The trial that hasn't reported

In September 2026 the phrase “first human study of BPC-157” started circulating again. It is worth being exact about what it can and cannot refer to, because the molecule has had a “first human study” announced roughly once a year since 2021, and each time the thing being announced was something else.

We checked the primary record rather than the headlines. PubMed, searched for BPC-157 in the window 1 August to 3 October 2026, returns reviews and a hydrogel-fabrication paper. The one substantive new paper is a critical review of the rodent ischemia-reperfusion literature, published 19 September 2026, which is a paper about the animal data and explicitly treats human and regulatory sources as context, not evidence (Demirtaş, Int J Mol Sci 2026). ClinicalTrials.gov lists one randomized trial recruiting and one not yet open, and neither has posted results. Reference

Every claim below is tagged by evidence tier, so you can see exactly where a statement comes from – settled regulatory fact, human data, animal work, or community report. The tiers grade provenance, not confidence: a well-replicated rodent study is still preclinical.

Reference

Established regulatory fact or a primary registry record.

Clinical

Data from human participants — here, uncontrolled pilots unless stated.

Preclinical

Animal or cell-culture data; no human equivalent published.

Community

Forum-reported and anecdotal — signal, not evidence.

Thirty-three years after the peptide was first described, this is every published report of BPC-157 given to people. All three come from the same private clinic in Florida, all three appeared in the same journal, and none has a control arm. Clinical

• 2021 — knee pain, n=16. A retrospective chart review: patients who had received an intra-articular injection six to twelve months earlier were telephoned and asked whether it helped. Twelve had BPC-157 alone (11 reported significant improvement); four had BPC-157 plus a product described as thymosin β4 (3 improved). No validated outcome instrument, no imaging, no comparison group, and the authors note the follow-up interval varied by patient.
• 2024 — interstitial cystitis, n=12. An open-label pilot: twelve women who had failed pentosan polysulfate were given 10 mg of compounded BPC-157 by injection around the inflamed bladder wall during a single cystoscopy. All twelve scored 5/5 on a Global Response Assessment afterwards; ten reported complete resolution. A 100% response in an open-label study of a pain syndrome with a large expected placebo component is a result that demands a control group, and none was run.
• 2025 — intravenous safety, n=2. Two adults, both of whom had already received intravenous BPC-157 before the study, were infused with 10 mg on day one and 20 mg on day two. Routine cardiac, hepatic, renal, thyroid and glucose labs did not move over three days, and neither reported side effects. The paper reports no pharmacokinetics despite the title of the registry entry some sites attach to it.

The sources are the papers themselves (knee, cystitis, infusion), and an independent 2025 scoping review from the University of Utah reaches the same count: three pilots, no adverse effects reported, no rigorous trial (McGuire et al., Curr Rev Musculoskelet Med 2025). Clinical

The genuinely new thing in 2026 is not a result but a design. In February 2026 Hudson Biotech opened enrolment for a Phase 2 trial in acute, MRI-confirmed grade II hamstring strain (NCT07437547). It is the first registered BPC-157 study with the features that make a human trial informative, and it is worth listing them, because they are exactly the features the three pilots lacked. Reference

• Randomized and placebo-controlled. 120 participants, allocated 1:1 to daily subcutaneous BPC-157 or matched placebo for 14 days, both arms on the same standardized rehabilitation programme.
• Quadruple-blinded. Participants, treating clinicians, investigators and outcome assessors are all blinded; the investigational pharmacy prepares identical prefilled syringes under a randomization code.
• Objective endpoints. Time to clearance for unrestricted sport by a blinded clinician plus a functional battery, and change in MRI injury volume at day 14 read by blinded central radiology. Not a phone survey.
• A timeline. Primary completion is estimated for February 2027 and study completion for February 2028. Nothing from this trial can have been published in September 2026.

A second study, a 30-person Phase 1 at the University of Arkansas on recovery after rotator-cuff repair, was first posted on 3 September 2026 and is not yet recruiting; its estimated start is January 2027 (NCT07803250). That posting is the most likely source of a “new human study” headline last month, and a registry record is not a study result. Reference

There is also a ghost. A Phase 1 safety and pharmacokinetics study of “PCO-02”, with BPC-157 as the active ingredient, was registered by a Croatian sponsor in 2015 with a Tijuana hospital as collaborator, planned 42 healthy volunteers, and was last updated the same year with an estimated completion of early 2016 (NCT02637284). Its status is “unknown” and no result was ever posted or published. A decade later, that is the only human pharmacokinetic study of BPC-157 that has ever been planned, and we still do not have one. Reference

The September 2026 paper is interesting precisely because it is not a human study. A cardiovascular surgeon at Gazi University searched the literature to 24 June 2026 and reviewed every rodent ischemia-reperfusion study of BPC-157: limb, gut, liver, brain, and the related major-vessel occlusion models. The findings are the ones the preclinical literature has always reported – less oxidative injury, modulated nitric-oxide responses, lower inflammatory and apoptotic markers, changes in the VEGFR2–Akt–eNOS axis (Demirtaş 2026). Preclinical

What is new is the author’s refusal to pool them. No meta-analysis was attempted because the organ systems, injury models, doses, routes, timings and outcomes were too heterogeneous to combine. The review describes an evidence base that “frequently relies on short observation periods, single-dose paradigms, and incompletely characterized risk-of-bias domains”, and its conclusion is that BPC-157 is a hypothesis-generating candidate for further preclinical work, with independent blinded replication, dose-response and therapeutic-window studies, PK/PD characterization and rigorous toxicology all required before controlled human trials would be justified. Preclinical

The other 2026 event that gets described as a change in BPC-157’s status is the FDA advisory-committee meeting of 23 July. The Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding BPC-157 to the 503A bulk-substances list, which would let compounding pharmacies prepare it under a prescription. The agency’s own review staff had recommended against, on the grounds that there was no controlled human evidence of benefit, inadequate safety information, and an unresolved question of what the compounded substance even is: the FDA briefing document notes that nominations did not agree on a single chemical identity for the material being sold as BPC-157 (FDA briefing document, July 2026). Reference

• It is advisory. The committee recommends; the agency decides, through rulemaking that is expected to take twelve to twenty-four months. Until then BPC-157 remains in Category 2 of the 503A list, as it has been since September 2023, and may not lawfully be compounded.
• It was not an evidence review. Several yes votes were cast explicitly on patient-demand and access grounds, with members acknowledging the data were incomplete. A vote on access policy is not a finding of efficacy, and it adds nothing to the human evidence table above.
• Identity is a safety question. A peptide that is sold under one name but reaches patients as more than one sequence, with impurity profiles no one has characterised, cannot have a safety record in any meaningful sense. That was the staff objection, and it stands regardless of the vote.

Two 2026 reviews written for clinicians land in the same place: a Sports Medicine review of approved and unapproved peptides describes rigorous human safety data for BPC-157 as scarce, and devotes a section to the placebo effect, amplified by social media, as a mediator of the benefit people report. Clinical

BPC-157 will have another “first human study” headline before the hamstring trial reports. Three questions sort them.

• Is there a control arm?. If no one received a placebo, the study cannot distinguish the drug from the injection, the attention, or regression to the mean. All three existing human reports fail this test. The hamstring trial passes it.
• Who measured the outcome, and how?. A phone call asking whether the knee feels better is not the same instrument as blinded MRI volumetry. The gap between those two is most of the gap between the 2021 paper and NCT07437547.
• Is it a result or a record?. A ClinicalTrials.gov posting, an advisory vote, a review of reviews, and an IRB approval are all reported as news. None is a result. A result has a date, a journal, participants, and numbers you can check against the registry's pre-specified endpoints.